InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,986.40
(
0.30%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
0.00%
)
Bitcoin
59,778.45
(
-1.32%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: bellweather1 post# 7683

Thursday, 05/05/2011 11:09:29 AM

Thursday, May 05, 2011 11:09:29 AM

Post# of 80490
I thought I read in a scientific journal somewhere (can't truly recall) that one of the ridaforolimus combination trials (with a Merck drug) in solid tumors showed efficacy in an endometrial subset (amongst others).

I'm sure this is the debate in Merck right now. Go solo, or go combo. And, the dinosaurs at Merck will send it through 24 different committees and one blue ribbon panel for 4 years to figure out which one to do.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up